Oruka Therapeutics, Inc.
ORKA
$68.71
$1.782.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -51.53% | 11.41% | -5.78% | -10.48% | -196.72% |
| Total Depreciation and Amortization | 168.75% | 51.35% | 81.82% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 111.72% | -15.79% | -12.06% | 436.87% | 3,560.47% |
| Change in Net Operating Assets | 150.56% | -33.05% | 93.81% | -121.76% | -144.47% |
| Cash from Operations | -12.98% | 6.16% | 22.35% | -109.78% | -12,322.02% |
| Capital Expenditure | -461.54% | -78.98% | 42.11% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -133.50% | 93.90% | -- | -- | -- |
| Cash from Investing | -133.68% | 93.88% | -71,507.60% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -99.21% | -59.75% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -99.26% | -59.90% | 106.86% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -88.25% | 87.11% | -93.47% | -44.00% | -20.71% |